Alveo Technologies Appoints Veteran Biotech and Diagnostics Leader to Board of Directors Roche executive Neil Gunn brings quarter-century of commercialization experience to infectious disease testing innovator News provided by Share this article Share this article ALAMEDA, Calif., May 13, 2021 /PRNewswire/ -- Alveo Technologies, Inc., an infectious disease testing leader, announced today biotechnology, diagnostics and medical device executive Neil Gunn has accepted an appointment to its board of directors. To download a photo of Neil Gunn, click here. Gunn, the retired president of Roche Sequencing Solutions, and current CEO of IDbyDNA, brings more than 25 years of healthcare industry experience to Alveo, with comprehensive knowledge and experience managing global product development, strategy development and commercial operations.